Reporter brief
A Double-Blind, Randomised, Placebo-Controlled Study Evaluating the Effects of a Novel Multi-Targeted Dermatologist-Formulated Oral Supplement on Skin, Hair, Sleep, Energy, Cognition, Libido, and Longevity
What happened
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The abstract provides no numerical results, effect sizes, or p-values, making it impossible to assess whether observed differences were meaningful or statistically significant. The supplement contains multiple active ingredients beyond omega-3s alone, so any effects cannot be attributed to omega-3 fatty acids specifically. A 12-week timeframe cannot establish whether any short-term changes persist or predict longer-term health outcomes like longevity, despite the study's title.
Study design and sample
Rct; Human.
Healthy adults aged 35 to 65 years
- Design
- Rct
- Sample
- —
- Journal
- IDI Skincare Limited
- Published
- Sep 18, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Sponsored by IDI Skincare Limited; conducted by Eurofins Product Testing Services Ltd (trading as Eurofins Alba) in Edinburgh, United Kingdom · Study sponsored by the manufacturer of the intervention product (IDI Skincare Limited), which is a substantial conflict of interest
Previous evidence
See the Omega-3 fatty acids timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.